加载中
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
常规交易时段
US$15.635
−US$0.395 · -2.46%
盘中时间采用ET。市场数据可能有所延迟。
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
日内区间
当前US$15.635
52周区间
当前US$15.635
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
29
偏贵
情绪
50
多空交织
风险
47
风险偏高
动量
63
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
日内区间
当前US$15.635
52周区间
当前US$15.635
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 310.7万 USD | — | 373.2万 USD | 264.1万 USD | 82.9万 USD |
| 毛利 | −310.7万 USD | — | −373.2万 USD | −264.1万 USD | −82.9万 USD |
| 研究与开发 | 9285.4万 USD | 1.15亿 USD | 1.04亿 USD | 1.12亿 USD | 7392.2万 USD |
| 销售、一般及管理费用 | 3855.1万 USD | 4172.8万 USD | 3770.4万 USD | 3299.3万 USD | 2261.6万 USD |
| 营业费用 | 1.28亿 USD | 1.8亿 USD | 1.38亿 USD | 2.45亿 USD | 1.24亿 USD |
| 利息收入 | 1660.7万 USD | 2009.3万 USD | 1671.2万 USD | 490.2万 USD | 19万 USD |
| 利息支出 | — | — | — | 2.01亿 USD | — |
| 折旧和摊销 | 310.7万 USD | 380.5万 USD | 373.2万 USD | 264.1万 USD | 82.9万 USD |
| 营业利润 | −1.31亿 USD | −1.8亿 USD | −1.42亿 USD | −2.47亿 USD | −1.25亿 USD |
| 净利润 | −1.25亿 USD | −1.62亿 USD | −1.25亿 USD | −2.43亿 USD | −1.23亿 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$22.50
上涨空间 43.91%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.75亿0.01%2.3万亿 USD0.03%US$381.67-0.07%
State Street SPDR S&P Biotech ETFXBI1.31亿1.33%98.74亿 USD0.35%US$152.82-0.62%
iShares Russell 2000 ETFIWM9270.83万0.12%787.4亿 USD0.19%US$278.46-0.17%
Vanguard Extended Market ETFVXF5620.19万0.06%954亿 USD0.05%US$234.28-0.31%
iShares Russell 2000 Growth ETFIWO3263.87万0.23%139.17亿 USD0.24%US$354.92-0.52%
iShares Biotechnology ETFIBB3067.18万0.28%108.2亿 USD0.44%US$205.59-0.44%
Schwab U.S. Small-Cap ETFSCHA2375.05万0.11%218.24亿 USD0.03%US$32.7576-0.10%
Vanguard Russell 2000 ETFVTWO2264.84万0.12%180亿 USD0.06%US$112.48-0.16%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
